Headlines about Titan Pharmaceuticals (NASDAQ:TTNP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Titan Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.5422910701225 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)? (finance.yahoo.com)
- Titan Pharmaceuticals, Inc. (TTNP) Forecasted to Earn FY2019 Earnings of ($0.27) Per Share (americanbankingnews.com)
- ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017 (finance.yahoo.com)
- Titan Pharma (TTNP) Enters Pact with Molteni to Market Probuphine in Europe (streetinsider.com)
- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Entry into a Material Definitive Agreement (4-traders.com)
Shares of Titan Pharmaceuticals (TTNP) traded down $0.05 during trading hours on Tuesday, hitting $1.50. The stock had a trading volume of 182,700 shares, compared to its average volume of 145,331. Titan Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $4.80. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 1.67.
Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.04). Titan Pharmaceuticals had a negative net margin of 6,757.29% and a negative return on equity of 146.81%. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.17 million. analysts anticipate that Titan Pharmaceuticals will post -0.67 EPS for the current year.
TTNP has been the topic of a number of recent research reports. Roth Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Titan Pharmaceuticals in a research note on Thursday, October 5th. ValuEngine cut Titan Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
COPYRIGHT VIOLATION NOTICE: “Titan Pharmaceuticals (TTNP) Receives Daily News Impact Rating of 0.05” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/12/05/titan-pharmaceuticals-ttnp-receives-daily-news-impact-rating-of-0-05.html.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.
Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.